{
  "id": 2934559,
  "title": "Restoring neurovascular coupling in Alzheimer's disease tauopathy through M1 mAChR modulation",
  "url": "https://urgent.news/2026/08/23/restoring-neurovascular-coupling-in-alzheimers-disease-tauopathy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-23T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.18.745579v1?rss=1"
  },
  "original_language": "en",
  "account": "Alzheimer's disease is marked by cognitive decline and early cerebrovascular dysfunction, including a reduction in neurovascular coupling (NVC) and cerebral blood flow (CBF). The accumulation of tau protein is a primary contributor to these issues, but there are few treatments that specifically target tau-induced neurovascular dysfunction. The M1 muscarinic acetylcholine receptor (M1 mAChR) shows promise as a therapeutic target due to its importance in cognitive function. Previous studies have shown that activating M1 mAChR can improve cognitive function and neuronal survival in Alzheimer's disease mouse models, although it is unclear if this approach can restore tau-induced NVC deficits.\n\nResearchers used P301S mice, a model of tauopathy, to investigate this question. They assessed cognitive function with the novel object recognition and Morris water maze tests, and NVC using laser speckle contrast imaging to measure changes in CBF in response to whisker stimulation. In these P301S tau mice, memory and recognition abilities were impaired, and their response to whisker stimulation was reduced, indicating an impaired NVC response. However, when treated with VU0486846, an M1 mAChR positive allosteric modulator, this impaired NVC response was reversed. This effect was more pronounced in female mice compared to males, indicating a potential sex-biased response to M1 mAChR modulation.\n\nThese findings suggest that activating the M1 mAChR could be a promising strategy for modifying Alzheimer's disease by reversing tau-induced neurovascular dysfunction. The observation that females showed earlier improvement highlights the influence of biological sex on therapeutic efficacy.",
  "summary": "Alzheimer's disease is characterized by progressive cognitive decline and early cerebrovascular dysfunction, including impaired neurovascular coupling (NVC) and reduced cerebral blood flow (CBF). Tau pathology is a major driver of these deficits, yet therapeutic strategies targeting tau-induced neurovascular dysfunction remain limited. The M1 muscarinic acetylcholine receptor (M1 mAChR) is a…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 4,
    "also_reported_by": [
      {
        "outlet": "Medical Xpress",
        "title": "Can we make blood transfusions safer by testing for proteins linked to strokes and Alzheimer's disease?",
        "url": "https://urgent.news/2026/08/21/can-we-make-blood-transfusions-safer-by-testing-for-proteins-linked",
        "published": "2026-08-21T17:20:05.000Z"
      },
      {
        "outlet": "Hacker News",
        "title": "FDA clears blood test to aid evaluation for Alzheimer's disease",
        "url": "https://urgent.news/2026/08/24/fda-clears-blood-test-to-aid-evaluation-for-alzheimers-disease",
        "published": "2026-08-24T06:30:07.000Z"
      },
      {
        "outlet": "Seeking Alpha News",
        "title": "Roche’s Alzheimer’s blood test wins FDA clearance",
        "url": "https://urgent.news/2026/08/24/roches-alzheimers-blood-test-wins-fda-clearance",
        "published": "2026-08-24T12:11:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}